Compare ARK Genomic Revolution ETF (ARKG) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs AngloGold Ashanti Limited — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while AngloGold Ashanti Limited trades at $80.25 (market cap $41.51B). The key difference: AngloGold Ashanti Limited pays a 5.6% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, AngloGold Ashanti Limited nearer its low. Which is the better fit depends on your goals.
| ARKG | AU | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $128.26 |
52-Week Low | $23.09 | $46.25 |
Market Cap | — | $41.51B |
Enterprise Value | — | $40.64B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
AngloGold Ashanti (AU) trades at $82.10, up 0.23% on the day, with a bearish technical signal but strong fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $2.52 versus $2.27 forecast. The company shows robust revenue growth, with 2025 revenue at $9.89 billion and net income margin of 26.64%. A proposed share repurchase program and a $1.16 dividend for H1 2026 highlight capital returns. Analyst consensus is bullish with a $116.25 price target, though technical indicators suggest near-term resistance.
Outlook remains positive driven by gold price strength and operational efficiency, but risks include geopolitical exposure and commodity volatility. The stock offers value with a P/E of 12.06 and high ROE of 45.39%, yet bearish technical trends and recent earnings misses in Q3 and Q4 2025 warrant caution. Institutional sentiment is mixed, with 64% buy ratings but technical selling pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
